Faricimab is a Monoclonal Antibody owned by F. Hoffmann-La Roche, and is involved in 20 clinical trials, of which 13 were completed, 6 are ongoing, and 1 is planned.

Faricimab is a bi-specific antibody acts as vascular endothelial growth factor A (VEGF-A) and angiopoietin 2 (Ang-2) inhibitor. VEGF-A is highly expressed in cancer cells and retina leading to the uncontrollable cell division and neovascularization. Angiopoietin-2 (Ang2) induces initiation of retinal neovascularization. Dual inhibition of ANG-2 and VEGF-A results in the suppression of cell division and inhibits angiogenesis.

The revenue for Faricimab is expected to reach a total of $45.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Faricimab NPV Report.

Faricimab is originated and owned by F. Hoffmann-La Roche.

Faricimab Overview

Faricimab (Vabysmo) is a humanized bispecific immunoglobulin G1 (IgG1) antibody. It is formulated as solution for intravitreal route of administration. Vabysmo is indicated for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).

Faricimab is under development for the treatment of diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, diabetic retinopathy, macular edema due to branch retinal vein occlusion, choroidal neovascularization secondary to age-related macular degeneration and wet age-related macular degeneration. The drug candidate is administered through intravitreal route. It is a new molecular entity (NME). RG-7716 is a bi-specific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Faricimab

Report Segments
  • Innovator (NME)
Drug Name
  • Faricimab
Administration Pathway
  • Intravitreal
Therapeutic Areas
  • Metabolic Disorders
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.